Inhibrx Biosciences, Inc. (INBX) Revenue History
Annual and quarterly revenue from 2016 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
INBX Revenue Growth
Revenue Breakdown (FY 2025)
INBX's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
INBX Revenue Analysis (2016–2025)
As of May 8, 2026, Inhibrx Biosciences, Inc. (INBX) generated trailing twelve-month (TTM) revenue of $1.3 million, reflecting significant decline in growth of -100.0% year-over-year. The most recent quarter (Q4 2025) recorded $0 in revenue.
Looking at the longer-term picture, INBX's 5-year compound annual growth rate (CAGR) stands at -36.7%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $12.8 million in 2020.
Revenue diversification analysis shows INBX's business is primarily driven by License, Non-Affiliate (100%). With over half of revenue concentrated in License, Non-Affiliate, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ARQT (+95.3% YoY), KYMR (-12.6% YoY), and TGTX (+81.3% YoY), INBX has underperformed the peer group in terms of revenue growth. Compare INBX vs ARQT →
INBX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| INBXCurrent | $1M | -100.0% | -36.7% | -10386.5% | |
 ARQT | $376M | +95.3% | - | -3.3% | |
 KYMR | $39M | -12.6% | +2.9% | -891.3% | |
 TGTX | $616M | +81.3% | +426.7% | 20.0% |
INBX Historical Revenue Data (2016–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $1.3M | +550.0% | $0 | - | $-135,025,000 | -10386.5% |
| 2024 | $200K | -88.9% | $-2,085,000 | -1042.5% | $-331,448,000 | -165724.0% |
| 2023 | $1.8M | -17.9% | $609K | 33.8% | $-219,221,000 | -12178.9% |
| 2022 | $2.2M | -69.2% | $-107,994,000 | -4926.7% | $-129,117,000 | -5890.4% |
| 2021 | $7.1M | -44.4% | $4.4M | 62.3% | $-76,564,000 | -1074.6% |
| 2020 | $12.8M | +40.9% | $-60,687,000 | -473.8% | $-67,443,000 | -526.6% |
| 2019 | $9.1M | +21.2% | $-38,814,000 | -426.9% | $-43,714,000 | -480.7% |
| 2018 | $7.5M | -5.7% | $-25,954,000 | -346.1% | $-29,513,000 | -393.5% |
| 2017 | $8.0M | +19.2% | $-17,560,000 | -220.9% | $-19,728,000 | -248.2% |
| 2016 | $6.7M | - | $-10,325,000 | -154.9% | $-12,146,000 | -182.2% |
See INBX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs INBX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare INBX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonINBX — Frequently Asked Questions
Quick answers to the most common questions about buying INBX stock.
Is INBX's revenue growth accelerating or slowing?
INBX revenue declined -100.0% year-over-year, contrasting with the 5-year CAGR of -36.7%. TTM revenue fell to $1M. This reverses the prior growth trend.
What is INBX's long-term revenue growth rate?
Inhibrx Biosciences, Inc.'s 5-year revenue CAGR of -36.7% reflects the variable expansion pattern. Current YoY growth of -100.0% is below this long-term average.
How is INBX's revenue distributed by segment?
INBX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2016-2025 are available for download. Segment mix reveals concentration and diversification trends.